• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Recent Advances in the Study of 5-morpholino-3(2H)-pyridazinone (CAS: 21131-06-6) in Chemical Biology and Pharmaceutical Research

The compound 5-morpholino-3(2H)-pyridazinone (CAS: 21131-06-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This heterocyclic compound, characterized by a pyridazinone core substituted with a morpholine moiety, has been the subject of numerous studies aimed at exploring its biological activities and pharmacological potential. Recent research has particularly focused on its role as a kinase inhibitor and its implications in treating various diseases, including cancer and inflammatory disorders.

A 2023 study published in the Journal of Medicinal Chemistry investigated the inhibitory effects of 5-morpholino-3(2H)-pyridazinone on specific protein kinases involved in cancer cell proliferation. The research team employed a combination of in vitro enzymatic assays and molecular docking simulations to elucidate the compound's mechanism of action. Their findings demonstrated potent inhibition of several oncogenic kinases, with IC50 values in the low micromolar range, suggesting its potential as a lead compound for anticancer drug development.

Further investigations into the pharmacokinetic properties of 5-morpholino-3(2H)-pyridazinone have revealed promising characteristics. A recent preclinical study reported in European Journal of Pharmaceutical Sciences (2024) examined the compound's metabolic stability, plasma protein binding, and membrane permeability. The results indicated favorable absorption and distribution profiles, with moderate plasma protein binding (approximately 75-80%) and good metabolic stability in human liver microsomes. These findings support the compound's potential for further development as a therapeutic agent.

Structural optimization studies have also been conducted to enhance the biological activity and selectivity of 5-morpholino-3(2H)-pyridazinone derivatives. Research published in Bioorganic & Medicinal Chemistry Letters (2023) described the synthesis and evaluation of various analogs with modifications at different positions of the pyridazinone ring. The study identified several derivatives with improved potency and selectivity against specific kinase targets, providing valuable structure-activity relationship (SAR) insights for future drug design efforts.

Beyond its kinase inhibitory properties, recent studies have explored additional biological activities of 5-morpholino-3(2H)-pyridazinone. A 2024 publication in ACS Chemical Biology reported its unexpected activity as a modulator of certain G-protein coupled receptors (GPCRs), opening new avenues for potential applications in neurological disorders. The compound demonstrated selective binding to specific GPCR subtypes involved in neurotransmitter regulation, suggesting possible utility in treating conditions such as Parkinson's disease or depression.

In conclusion, the growing body of research on 5-morpholino-3(2H)-pyridazinone (CAS: 21131-06-6) highlights its multifaceted potential in pharmaceutical development. Its dual activity as both a kinase inhibitor and GPCR modulator, combined with favorable pharmacokinetic properties, positions this compound as a promising candidate for further investigation. Future research directions may include comprehensive toxicity studies, formulation optimization, and expanded preclinical evaluations to fully realize its therapeutic potential across multiple disease areas.

• 5592-57-4(3(2H)-Pyridazinone,4-bromo-5-(4-morpholinyl)-)
• 41773-19-7(5-(dimethylamino)-2,3-dihydropyridazin-3-one hydrochloride)
• 477845-70-8(5-morpholino-2-(2-oxopropyl)-3(2H)-pyridazinone)
• 159430-52-1(5-(piperazin-1-yl)-2,3-dihydropyridazin-3-one)
• 1201176-32-0(5-(4-methyl-1-piperazinyl)-3(2H)-Pyridazinone)
• 1421602-72-3(5-(Ethylamino)-2,3-dihydropyridazin-3-one)
• 344770-47-4
• 69123-72-4(3(2H)-Pyridazinone, 2-methyl-5-(4-morpholinyl)-)
• 478006-77-8(3(2H)-Pyridazinone, 5-[bis(2-hydroxyethyl)amino]-)
• 82226-43-5(5-(dimethylamino)-2,3-dihydropyridazin-3-one)